Bristol Myers Squibb(CELG-RI)

PRINCETON, NJPharmaceutical1 H-1B visas (FY2023)

Focus: Bristol Myers Squibb is a major integrated pharma company with ~34,300 employees focused on oncology, hematology, immunology, cardiovascular, and neuroscience therapeutics. A global top-tier player generating $45–46B in annual revenue with strong small molecule and biologic capabilities.

Oncology Hematology Immunology Cardiovascular

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

34,300

Open Jobs

737+236 this month

Hot — 625 jobs added in 30d

Net +236 (625 new, 389 removed). Aggressive expansion phase.

5 recent layoff filings (12 mo) — 1,016 affected

4/1/2026 — Lawrence Twp, NJ · 206 affected · Layoff
4/1/2026 — Lawrence Twp, NJ · 206 affected · Layoff
2/1/2026 — Lawrence Twp, NJ · 247 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

Should You Work at Bristol Myers Squibb?

AI assessment

Strong for careers in oncology, immunology, and manufacturing; risky long-term due to heavy ELIQUIS dependency, imminent patent cliffs, and modest pipeline to offset losses.

Why Work Here

Portfolio leadership in oncology (REVLIMID, POMALYST, multiple IOO combinations) and cardiovascular (ELIQUIS dominance) provides exposure to blockbuster drug lifecycles and competitive markets.

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

2 imminent

REVLIMID

Hiring

Stable

Revenue

$45.0B

FY2025

Key Products

ELIQUIS

Atrial fibrillation, venous thromboembolism, stroke prevention

$18.3B Part D

Peak

Help build intelligence for Bristol Myers Squibb

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

BMS-986094/INX-08189

Healthy

N/A

Clinical Trials (1)

NCT01732848A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

N/A

The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'

HIV Positive

N/A

Didanosine

HIV Infections

N/A

Clinical Trials (5)

NCT00197613The Adult Antiretroviral Treatment and Resistance Study (Tshepo)

Phase 3

NCT00002429Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

Phase 3

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

HIV Infections

N/A

Clinical Trials (1)

NCT00135447A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

N/A

Iberdomide

Various

N/A

Clinical Trials (5)

NCT04975997Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3

NCT05558319NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

Healthy Participants

N/A

Clinical Trials (1)

NCT05539976A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

N/A

There is no intervention, but a diagnosis.

Rheumatologic Disorder

N/A

Clinical Trials (1)

NCT03843658Identifying Novel Biomarkers in Early Rheumatology Patients

N/A

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cance

Carcinoma, Non-Small-Cell Lung

N/A

Clinical Trials (1)

NCT05250817A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

N/A

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Anticoagulation

N/A

Clinical Trials (1)

NCT02921126Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

N/A

ABI-007

Pancreatic Cancer

N/A

Clinical Trials (5)

NCT00844649Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Phase 3

NCT00540514Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Palliative care assessment

Advanced Cancer

N/A

Clinical Trials (1)

NCT03837132Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer

N/A

Abraxane

Metastatic Pancreatic Cancer

N/A

Clinical Trials (1)

NCT02555813Treatment of Pancreatic Cancer With Abraxane

N/A

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Medication Non-adherence

N/A

Clinical Trials (1)

NCT00998127Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

N/A

Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

VEXAS Syndrome

N/A

Clinical Trials (1)

NCT06377462Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

N/A

The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuber

Rheumatic Disease

N/A

Clinical Trials (1)

NCT01685905The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection

N/A

Anti-IL8

Various

N/A

Clinical Trials (1)

NCT05210894Expanded Access for Anti-IL8

N/A

Immunotherapy

Cancer

N/A

Clinical Trials (5)

NCT05002569A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Phase 3

NCT04410445Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

Gastrointestinal Hemorrhage

N/A

Clinical Trials (1)

NCT02514304Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

N/A

SURGE

Gastrointestinal Cancer

N/A

Clinical Trials (5)

NCT01884337Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Phase 4

NCT01675076Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Screening DIVA - Diffuse Vascular Disease

Peripheral Vascular Diseases

N/A

Clinical Trials (1)

NCT01076738Screening DIVA - Diffuse Vascular Disease

N/A

Ultrasound

Thrombosis

N/A

Clinical Trials (2)

NCT03411850Sjogrens Syndrome Measured by Ultrasound

Phase 2

NCT01137578Pediatric Catheter-related Thrombosis Imaging Study

N/A

A Study of Factors That Affect Long-Term Kidney Transplant Function

Kidney Transplant

N/A

Practical Geriatric Assessment

Geriatric Assessment

N/A

Clinical Trials (1)

NCT06870617Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

N/A

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Hodgkin's Disease

N/A

Clinical Trials (1)

NCT02856646Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

N/A

ImmunOncoTool Condition

Cancer

N/A

Clinical Trials (1)

NCT04513678Development of ImmunOncoTool

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

HIV Infections

N/A

Patient Navigation Program

Caregiver

N/A

Clinical Trials (1)

NCT03867916Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients

N/A

BET Inhibitor

Various

N/A

Clinical Trials (1)

NCT05301972Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor

N/A

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

Renal Cancer

N/A

Assessment of Geriatric Evaluations Impact on New AML Guidance

AML, Adult

N/A

Clinical Trials (1)

NCT05909501Assessment of Geriatric Evaluations Impact on New AML Guidance

N/A

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

HIV

N/A

Clinical Trials (1)

NCT03324633Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

N/A

Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation

Burns

N/A

Clinical Trials (1)

NCT00326729Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation

N/A

National Pregnancy Registry for Psychiatric Medications

Pregnant Women

N/A

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial

Urinary Bladder Neoplasms

N/A

Collect retrospectively clinical data on reproductive outcomes

Embryo Disorder

N/A

Clinical Trials (1)

NCT04734769Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications

N/A

Interview

Caregiver

N/A

Clinical Trials (1)

NCT04051216The SMART CART Study: Health Information Technology

N/A

Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using

Elderly

N/A

Clinical Trials (1)

NCT02401854Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using an External Loop Recorder

N/A

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Hematopathology Eligible or CAR-t Cell Treatment

N/A

Ex-vivo analysis

HIV

N/A

Clinical Trials (1)

NCT02628340Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients

N/A

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Onco

Advanced Solid Tumors or Hematologic Malignancies

N/A

Clinical Trials (1)

NCT04389541Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

N/A

Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Com

Premature Endothelial Dysfunction

N/A

Clinical Trials (1)

NCT01499732Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects

N/A

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

HIV Infections

N/A

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progress

Rheumatoid Lung

N/A

Clinical Trials (1)

NCT04136223Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression

N/A

Samples collection: Plasma

CNS Metastases

N/A

Clinical Trials (1)

NCT04109131A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

N/A

Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

HIV Infections

N/A

Clinical Trials (1)

NCT00575939Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

N/A

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

18F-BMS-986229 Injection

Esophagogastric Cancer

N/A

Clinical Trials (1)

NCT04161781A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

N/A

Recommendation for treatment with immunotherapy

Metastatic Solid Tumor

N/A

Clinical Trials (1)

NCT04447651Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

N/A

Comparative Tolerability of Protease Inhibitors

HIV

N/A

Clinical Trials (1)

NCT01450618Comparative Tolerability of Protease Inhibitors

N/A

3H-Cholesterol

Healthy

N/A

Clinical Trials (1)

NCT01031862BMS Reverse Cholesterol Transport (RCT) Study

N/A

Interview Prep Quick Facts

Portfolio: 500 approved products, 161 clinical trials

Top TAs: Oncology, Infectious Diseases, Immunology

H-1B (2023): 1 approval

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 737 active jobs

Portfolio Health

Pre-Launch205 (41%)

Growth6 (1%)

Peak21 (4%)

LOE Approaching92 (18%)

Post-LOE176 (35%)

500 total products

Therapeutic Area Focus

Oncology

84 marketed2007 pipeline

Infectious Diseases

51 marketed295 pipeline

Immunology

62 marketed242 pipeline

Cardiovascular

64 marketed194 pipeline

Financials (FY2025)

Revenue

$45.0B2%

R&D Spend

$9.3B(21%)2%

Net Income

$8.0B

Hiring Trend

Stable

737

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2024-02

2,200 employees affected— New Brunswick, NJ

Source: state DOL filings, aggregated via Big Local News

Feb 2024 WARN filing for 2,200 job cuts in New Brunswick, NJ, attributed to 'strategic realignment,' signaling cost pressures ahead of patent cliff.

Immediate hiring freeze risk in corporate and R&D functions; manufacturing roles appear safer but supply chain roles may face efficiency pressures post-2026.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol.

Transplantation direct

2026

PMID:41799026

Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS(G12C) Active-State Inhibition.

CLINICAL PHARMACOLOGY Intramuscular Administration Amikacin is rapidly absorbed after intramuscular administration. In normal adult volunteers, average peak serum concentrations of about 12, 16, and 21 mcg/mL are obtained 1 hour after intramuscular administration of 250 mg (3.7 mg/kg), 375 mg (5 mg/kg), 500 mg (7.5 mg/kg), single doses, respectively. At 10 hours, serum levels are about 0.3 mcg/mL, 1.2 mcg/mL, and 2.1 mcg/mL, respectively. Tolerance studies in normal volunteers reveal that amikacin is well tolerated locally following repeated intramuscular dosing, and when given at maximally recommended doses, no ototoxicity or nephrotoxicity has been reported. There is no evidence of drug accumulation with repeated dosing for 10 days when administered according to recommended doses. With normal renal function, about 91.9% of an intramuscular dose is excreted unchanged in the urine in the first 8 hours, and 98.2% within 24 hours. Mean urine concentrations for 6 hours are 563 mcg/mL following a 250 mg dose, 697 mcg/mL following a 375 mg dose, and 832 mcg/mL following a 500 mg dose. Preliminary intramuscular studies in newborns of different weights (less than 1.5 kg, 1.5 to 2 kg, over 2 kg) at a dose of 7.5 mg/kg revealed that, like other aminoglycosides, serum half-life values were correlated inversely with post-natal age and renal clearances of amikacin. The volume of distribution indicates that amikacin, like other aminoglycosides, remains primarily in the extracellular fluid space of neonates. Repeated dosing every 12 hours in all the above groups did not demonstrate accumulation after 5 days. Intravenous Administration Single doses of 500 mg (7.5 mg/kg) administered to normal adults as an infusion over a period of 30 minutes produced a mean peak serum concentration of 38 mcg/mL at the end of the infusion, and levels of 24 mcg/mL, 18 mcg/mL, and 0.75 mcg/mL at 30 minutes, 1 hour, and 10 hours post-infusion, respectively. Eighty-four percent of the administered dose was excreted in the urine in 9 hours and about 94% within 24 hours.Repeat infusions of 7.5 mg/kg every 12 hours in normal adults were well tolerated and caused no drug accumulation. General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight). By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%. The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function. Amikacin is excreted primarily by glomerular filtration. Patients with impaired renal function or diminished glomerular filtration pressure excrete the drug much more slowly (effectively prolonging the serum half-life). Therefore, renal function should be monitored carefully and dosage adjusted accordingly (see suggested dosage schedule under ) Following administration at the recommended

Bristol Myers Squibb(CELG-RI)

Should You Work at Bristol Myers Squibb?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (49)

Key Products by Revenue

Other Products (20)

Pipeline & Clinical Trials

Open Jobs (737)

Sr Global Trial Acceleration Associate

Business Analyst II – International Markets

Associate Director, Biostatistics

Senior Specialist, Quality Assurance Technical Operations

Account Executive, MAVA

Principal AI Engineer

Software Engineer II, PDS BI&T

Associate Director, Research BI&T

Account executive

(Sr.) Account Executive, MAVA

Senior Medical Advisor, Pipeline Lead

Executive Director, Strategic Risk Portfolio & Intelligence

Manufacturing Associate 1

Senior Specialist, QA Operations Investigations

Director, eCOA Management

Associate Director, Hematology Regional Marketing (RMK) – East

Associate Scientist, Automation Process Development

Senior Manager API Quality Operations

Senior District Business Manager, Neuro-Cobenfy- Carolinas

Global Trial Associate

Senior Therapeutic Area Specialist, Neuroscience - Cobenfy – Omaha, NE

Radiopharmaceutical Applications Team Lead

Medical Science Liaison, Camzyos (DC, DE, MD, VA)

Associate Director, Hematology Regional Marketing (RMK) – Mid West

Therapeutic Area Specialist (TAS), Hematology - Bucharest, Iasi

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Research Publications(10)